Glioblastoma (GBM) remains the most devastating primary central nervous system
malignancy with a median survival of around 15 months. The past decades of research have …

O6-methylguanine-DNA-methyltransferase (MGMT) is a DNA repair enzyme, which reverses
the alkylation of guanine O6 through directtransfer of the methyl group, maintains the gene …

Key molecular regulators of acquired radiation resistance in recurrent glioblastoma (GBM)
are largely unknown, with a dearth of accurate preclinical models. To address this, we …

Background Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are
multisystemic autoimmune diseases with multifactorial nature. Considering the limitations of …

Background Promoter methylation of the DNA repair gene O 6-methylguanine-DNA
methyltransferase (MGMT) is an acknowledged predictive epigenetic marker in glioblastoma …

Background For recurrent glioblastoma (GB) patients, several therapy options have been
established over the last years such as more aggressive surgery, re-irradiation or …

Temozolomide is an imidazotetrazine with a long history in oncology especially for the high
grade malignant glioma and metastatic melanoma. However, last year's new indications for …

Triple-negative breast cancer (TNBC) is typically treated with chemotherapeutic agents,
including carboplatin (Cb), an DNA platinating agent. The O6-methylguanine-DNA …

Background and aim Glioblastoma multiforme (GBM) is primary brain tumor grade IV
characterized by fast cell proliferation, high mortality and morbidity and most lethal gliomas …

Background There are limited studies on treatment strategies and associated clinical
outcomes in patients with secondary glioblastoma (sGBM). We sought to investigate the …